Dissolution of the left atrial appendage thrombus with rivaroxaban therapy

Cerebrovascular Diseases

Volumn 36, Issue 4, 2013, Pages 322-323

  Takasugi, Junji ^a   Yamagami, Hiroshi ^a   Okata, Takuya ^a   Toyoda, Kazunori ^a   Nagatsuka, Kazuyuki ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; RIVAROXABAN;

AGED; ANTICOAGULANT THERAPY; APHASIA; ARM WEAKNESS; ATRIAL FIBRILLATION; BLOOD CLOT LYSIS; BRAIN INFARCTION; CASE REPORT; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DISSOLUTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOLLOW UP; HEART ATRIUM APPENDAGE; HEART ATRIUM THROMBOSIS; HEMIPARESIS; HUMAN; MALE; MIDDLE CEREBRAL ARTERY; NEUROIMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL ATRIAL FIBRILLATION; PRIORITY JOURNAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MORPHOLINES; RECURRENCE; STROKE; THIOPHENES; THROMBOSIS; TREATMENT OUTCOME;

EID: 84886730834     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000354315     Document Type: Note

References (10)

1. European Atrial Fibrillation Trial Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
2. Collins LJ, Silverman DI, Douglas PS, Manning WJ: Cardioversion of nonrheumatic atrial fibrillation: reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995; 92: 160-163.
3. Jaber WA, Prior DL, Thamilarasan M, Grimm RA, Thomas JD, Klein AL, Asher CR: Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. Am Heart J 2000; 140: 150-156.
4. Yasaka M, Yamaguchi T, Miyashita T, Tsuchiya T: Regression of intracardiac thrombus after embolic stroke. Stroke 1990; 21: 1540-1544.
5. Kern R, Nagayama M, Toyoda K, Steiner T, Hennerici MG, Shinohara Y: Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis 2013; 35: 402-418.
6. Vidal A, Vanerio G: Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis 2012; 34: 545-547.
7. Hammerstingl C, Potzsch B, Nickenig G: Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost 2013; 109: 583-584.
8. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM: In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-888.
9. Varin R, Mirshahi S, Mirshahi P, Klein C, Jamshedov J, Chidiac J, Perzborn E, Mirshahi M, Soria C, Soria J: Whole blood clots are more resistant to lysis than plasma clots-greater efficacy of rivaroxaban. Thromb Res 2013; 131: 100-109.
10. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M, J-ROCKET AF Study Investigators: Rivaroxaban versus warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J 2012; 76: 2104-2111.